Understanding cell division is critical to understanding and treating cancer. The spindle assembly checkpoint (SAC) is a critical junction delaying aberrant mitosis to enable complete chromosome segregation and ensure proper mitotic progression. Activation of the SAC signaling pathway results in the inhibition of the 1.2 MDa ubiquitin ligase Anaphase-Promoting Complex/Cyclosome (APC) by the four-protein Mitotic Checkpoint Complex (MCC). However, the SAC barrier to cell division is deactivated by the poorly described MCC disassembly process once all sister chromatids achieve correct bipolar orientation. Dismantling MCC is an energy-dependent activity that requires the APC ubiquitination machinery, its associated proteins, and additional checkpoint-silencing factors. MCC ablation permits APC to trigger the ubiquitin-dependent proteasomal destruction of several key regulators of mitosis, such as Cyclin B and Securin, resulting in anaphase onset. As I pursue an independent research career examining how APC activity is modulated throughout the cell cycle, I will use a hybrid technological approach involving enzyme kinetics, crosslinking, electron microscopy, NMR, crystallography, and cell-based assays to dissect the biochemical (Aim 1) and structural (Aim 2) mechanisms of MCC disassembly by APC-mediated ubiquitination and other checkpoint termination factors. These results will have important implications for the fundamental understanding of cell cycle regulation and may enable the development of therapeutics for numerous cancers.

Public Health Relevance

Uncontrolled cell division and deregulation of the cell cycle are hallmarks of cancer. The regulation of two large, multi-protein complexes, Anaphase-Promoting Complex/Cyclosome (APC) and the Mitotic Checkpoint Complex (MCC), ensures faithful chromosome segregation. Therefore, a detailed understanding of this balance will provide unprecedented insights into the cell cycle and illuminate approaches for targeting APC and its associated proteins to develop novel anti-cancer therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Career Transition Award (K22)
Project #
1K22CA216327-01
Application #
9308547
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Jakowlew, Sonia B
Project Start
2017-09-01
Project End
2018-07-31
Budget Start
2017-09-01
Budget End
2018-07-31
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599